- Home
- MOLN
as 11-07-2025 3:01pm EST
Stocks
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
| Founded: | 2004 | Country: | Switzerland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 142.5M | IPO Year: | 2021 |
| Target Price: | $4.00 | AVG Volume (30 days): | 7.2K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.36 - $6.24 | Next Earning Date: | 10-30-2025 |
| Revenue: | N/A | Revenue Growth: | -29.38% |
| Revenue Growth (this year): | -79.48% | Revenue Growth (next year): | 1000.00% |
Latest Molecular Partners AG News
MOLN Breaking Stock News: Dive into MOLN Ticker-Specific Updates for Smart Investing
GlobeNewswire
7 days ago
Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting
GlobeNewswire
7 days ago
Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025
GlobeNewswire
11 days ago
Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025
CNW Group
16 days ago
MOVA Debuts at Equip Exposition 2025, Redefining the Future of Smart Outdoor Solutions
Newsfile
16 days ago
Canadian Picker Legend Wayne Learie Retires After 60 Years - 2,000 Rare Collectibles Head to Global Auction
Benzinga
16 days ago
A Study Says San Francisco's Housing Costs Have Returned To 'Normal' Levels – So Why Is It Still So Unaffordable?
24/7 Wall St.
16 days ago
Insiders Are Scooping Up Shares of a Miner, a Driller, and a Biotech
Yahoo Finance
16 days ago
How to manage financial caregiving for an aging parent
Compare MOLN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MOLN Molecular Partners AG - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.